30 closest matches · ranked by relevance
Neurodegenerative Disease · Weight Loss · Amyotrophic Lateral Sclerosis
Primary: Estimated Mean Change in Weight From Baseline to 6 Months — -0.1; -0.2; -1.2 kg
Cardiovascular Diseases · Hepatitis C · Hiv
Primary: Change in Cardiovascular Disease Risk From Baseline to After Functional Cure of Hepatitis C, as Measured by High-sensitivity C-reactive Protein — 0.6; 0 mg/L
Sudden Cardiac Death · Sudden Cardiac Arrest · Heart Failure
Primary: Percentage of Patients With LVEF Recovery at Day 90 and 180 — 222; 0; 0; 0 Participants
Congestive Heart Failure · Heart Failure, Diastolic
Primary: the Safety Profile of CAP 1002; Any Subjects Experiencing Any Safety Related Events During or Post Intracoronary Delivery and During the Follow up Period. — 0; 1…
Cardiovascular Diseases · Depression
Primary: Change (Per Day) in Average Daily Steps From Baseline — 2.8; 2.9; -8.2; -1.2 Change (per day) in Average Daily Steps — p=0.973
Head and Neck Cancer · Survivorship · Nutrition Aspect of Cancer
Primary: Number of Participants Meeting Patient-Caregiver Session and Care Plan Acceptability Criteria — 18; 18; 17; 15 participants
Human Immunodeficiency Virus (HIV) Positive
Primary: Number of Participants With Viral Load Suppression — 210; 213 Participants — p=0.220
Cardiac Rehabilitation
Primary: Participation in Cardiac Rehabilitation — 231; 252 Participants — p=0.80
Colorectal Cancer · Breast Cancer · Coronary Heart Disease
Primary: Number of Subjects Who Discussed Disease Risk With Primary Care Provider — 905; 841 Participants
Diabetes Mellitus, Type 2
Primary: A1c (Laboratory Assessment) — 35; 35 Participants
Weight Loss · Pre Diabetes · Overweight and Obesity
Primary: Mean Percent Body Weight (Pounds) Change — 0.88; 0.53; -1.06 percent weight change — p=0.1013
Stress
Primary: Number of Participants Reporting Pediatric Symptoms as Assessed by the Pediatric Symptom Checklist-17 (PSC-17) — 3; 2; 4; 3 participants
Hypertension With Complications and Secondary Hypertension · Overweight and Obesity · Lipid Metabolism Disorders
Primary: Cardiovascular Disease Risk Factors — 3; 4; 5; 7 participants
HIV-1 Infection
Primary: Absolute Change in Relative FMD (%) — 0.60; 0.50 % FMD — p=0.28
Estrogen Deficiency · Cardiovascular Disease (CVD) · Functional Hypothalamic Amenorrhea
Primary: Rate of Change of Reactive Hyperemia Index (RHI) by Peripheral Arterial Tonometry — 0.20; 0.25 change of RHI
Hypertension · High Blood Pressure · Ventricular Hypertrophy
Primary: Clinically Significant Difference in Blood Pressure Lowering, Health Status and Quality of Life — -3.3; -4.9 mm Hg
Child Behavior · Child Health · Child, Preschool
Primary: Child Behavior Problems — 132.8; 145.4 score on a scale
Heart Failure With Preserved Ejection Fraction
Primary: Change in Plasma N-terminal Proatrial Natriuretic Peptide (NT proANP) — 47.4; 46.4 pg/mL
Obesity
Primary: Change in Weight — -0.24; 0.49 Kg
Cardiovascular Diseases · Heart Diseases · HIV Infections
Primary: Triglycerides — 199; 216.9; 155.1; 177.6 mg/dL
Diabetes Mellitus · Hyperglycemia · Obesity
Primary: Percent Change in Body Weight — -0.15; -1.42 percentage of change — p=0.017
Chronic Disease · Frail · Diabetes Mellitus
Primary: Feasibility - Recruitment — 9; 15; 9; 11 # of participants @ start of study
Cardiovascular Disease
Primary: Change in Pulse Wave Velocity (PWV) — -0.25; -0.16 m/s
Duchenne Muscular Dystrophy
Primary: Number of Subjects With an Adverse Event. — 1; 0; 0; 0 participants
Metabolic Syndrome
Primary: Feasibility of the Diet Intervention — 4782 prescribed diet visits
Cardiopulmonary Disease
Primary: Correlation Coefficient for Accuracy of Test Device vs Reference Device — 0.99; 0.95 Correlation Coefficient
Lipid Disorder
Primary: Low-density Lipoprotein Cholesterol (LDL-C) Levels at Baseline and Day 30 — 110; 84.0 mg/dL
HIV Infections
Primary: Left Ventricular Mass Index — 67; 60 g/m2 — p=0.27
Cardiovascular Diseases
Primary: Proportion of Surveys/Tasks Returned in Period 1 — 0.85; 0.85 proportion of surveys returned
Chronic Kidney Diseases
Primary: Change From Baseline in eGFR at 3 Months (Patient-specific) — -1.71; -4.12 ml/min/1.73m^2